Media

This publication describes 3 cases where patients with chronic and recurrent S. aureus-related dermatoses were successfully treated with Staphefekt SA.100, the active ingredient of Gladskin. The results indicate that targeted...

This study shows that the skin-microbiome in patients with eczema/atopic dermatitis is characterized by overgrowth of S. aureus bacteria. More overgrowth was linked to more severe symptoms. On the other hand a...

With Staphefekt, the first targeted therapy against S. aureus is available for long-term daily maintenance therapy, aimed at decreasing the burden of skin colonisation and preventing progression to inflammation and...

These results demonstrate the importance of colonization with S. aureus in Atopic Dermatitis... At present, new targeted antimicrobial therapies (such as lysins) are being developed, which are directed against single...

Johan Frieling has recently been appointed as the new chief medical officer of Micreos. EPM talks to him about his experience in the pharmaceutical sector and the company’s new antibiotic...

The endolysin Staphefekt is the active ingredient of Gladskin products and it could play a big role in the maintenance treatment of chronic skin conditions where bacteria are thought to...